Learn how you can trust Dianthus to efficiently evaluate the binary and ternary complex formed by PROTACs, ubiquitin ligase, and the protein of interest.
Have a question about Dianthus?
Contact SpecialistSee more related content
Three things we took away from attending Drug Discovery Chemistry in 2024
Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful...
Attend these targeted protein degradation conferences in 2024 to stay in the know
Attending dedicated targeted protein degradation conferences and tracks is a great way to keep up with this rapidly evolving field. Here are 8 conferences you’ll want to attend in 2024.
22:23Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
16:42How to keep your degrader pipeline moving forward with Dianthus
The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
8 Targeted Protein Degradation conferences in 2023 you won’t want to miss
2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...
37:25Put your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
59:35Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
Why so many companies are betting on PROTACs as a superior therapeutic modality
One advantage of PROTACs is their unique mode of action — the induced proximity of an E3 ligase and the protein of interest (POI) triggers the ubiquitination and then degradation of the POI by the...
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
10 terms to help you more easily understand targeted protein degradation
If you’re new to the world of TPD or you’re trying to keep up with all developments in this fast-moving field, here are some terms and definitions that will help you.
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
The total protein degradation modality — locally and specifically targeting the disease-causing proteins and degrading their toxic aggregates — promises to be revolutionary. But the development of...
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
